169339-32-6Relevant academic research and scientific papers
Synthesis of 14C-labelled CGS 16949A (fadrozole HCI), a potent aromatase inhibitor
Markus, Bohdan,Allentoff, Alban J.,Desai, Mahesh,Chaudhuri, Naba K.,Duelfer, Timothy
, p. 885 - 890 (1997)
CGS 16949A (Fadrozole HCI) is an aromatase inhibitor currently used in Japan for the treatment of estrogen-dependent cancer. A 14C-labeled form of this compound was synthesized for metabolism and pharmacokinetic studies. The synthesis pathway includes six steps, which are shown in synthetic Scheme 2. Initially, 4-bromotoluene was reacted with [14C]CuCN to yield 4- tolunitrile-[14C]-cyano. The nitrile was brominated on the α carbon to give an intermediate that was used to N-alkylate a known imidazole analogue. The product was treated with thionyl chloride to convert a 3-hydroxy propyl moiety to its chloro analogue. Treatment with potassium butoxide gave [14C] fadrozole as the free base via ring closure. Hydrogen chloride gas was used to give the desired salt [14C]CGS 16949A. Using this procedure, [14C]CGS 16949A was prepared with 97% radiochemical purity. The overall radiochemical yield for the synthesis was 1% from [14C]KCN.
Synthesis of [14C2] SDZ FOX 988, a hypoglycemic agent
Sunay,Talbot,Prasad,Lee,Jones
, p. 529 - 535 (1995)
4-(2,2-dimethyl-1-oxopropyl-1-[14C])-4-(2,2-dimethyl-1-oxopropyl-1-[ 14C])-phenyl(methoxyimino)-benzoic acid, methyl ester, [14C2] SDZ FOX 988, doubly labelled in the two keto carbons, was prepared from 4-bromotoluene in four steps. The final condensation featured a novel method for preparation of N-oxyimidic acid derivatives.
